Gulfstream Daily Brief

Regulatory intelligence and policy · Issue 031

FDA renews cell and gene therapy advisory committee, EMA posts revised VICH testing guideline

Today’s regulatory updates cover continued FDA access to external cell and gene therapy expertise and a revised European veterinary biologicals testing guideline.

By Scott Morvay, Founder October 14, 2026 Official sources linked

FDA

FDA renews cell and gene therapy advisory committee

The Commissioner renewed the Cellular, Tissue, and Gene Therapies Advisory Committee for two additional years. Its new charter remains in effect until October 28, 2028.

Read the official source

EMA

EMA publishes revised VICH guideline on Mycoplasma testing

EMA published Revision 1 of VICH GL34, addressing testing for the detection of Mycoplasma contamination in veterinary biologicals.

Read the official source

Why this matters

The FDA renewal preserves a formal channel for independent advice on cellular, tissue, and gene therapies through 2028. The revised VICH guideline gives veterinary biologicals teams an updated reference for Mycoplasma contamination testing.

Scott Morvay

Founder, Gulfstream Intelligence

This brief provides general regulatory news and educational information. It is not legal or regulatory advice.